Eribulin normalizes pancreatic cancer-associated fibroblasts by simulating selected features of TGFβ inhibition.

ABSTRACT:

Background

Less than 11% of pancreatic cancer patients survive 5-years post-diagnosis. The unique biology of pancreatic cancer includes a significant expansion of its desmoplastic tumor microenvironment, wherein cancer-associated fibroblasts (CAFs) and their self-produced extracellular matrix are key components. CAF functions are both tumor-supportive and tumor-suppressive, while normal fibroblastic cells are solely tumor-suppressive. Knowing that CAF-eliminating drugs are ineffective and can accelerate cancer progression, therapies that "normalize" CAF function are highly pursued. Eribulin is a well-tolerated anti-microtubule drug used to treat a plethora of neoplasias, including advanced/metastatic cancers. Importantly, eribulin can inhibit epithelial to mesenchymal transition vi

SUBMITTER: Luong T 

PROVIDER: S-EPMC9719234 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature